Stocktoria
Clene Inc. CLNN
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2018-08-27
Clene Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $200,000 | $342,000 | $654,000 | $473,000 | $723,000 |
| R&D expense | $14.0M | $20.1M | $26.7M | $31.9M | $28.4M |
| Operating income | -$23.1M | -$33.1M | -$40.5M | -$48.4M | -$50.0M |
| Interest expense | — | — | $4.6M | $3.3M | $870,000 |
| Income tax | $0 | $0 | $0 | $0 | -$428,000 |
| Net income | -$26.2M | -$39.4M | -$49.5M | -$29.9M | -$9.7M |
| Operating cash flow | -$18.5M | -$21.3M | -$30.2M | -$39.0M | -$34.6M |
| Free cash flow | -$18.6M | -$21.3M | -$30.5M | -$44.2M | -$36.0M |
| Cash & equivalents | $5.2M | $12.2M | $28.8M | $18.3M | $50.3M |
| Inventory | $37,000 | $68,000 | $37,000 | $43,000 | $41,000 |
| Total assets | $18.1M | $27.3M | $52.3M | $44.5M | $63.1M |
| Total liabilities | $35.7M | $36.2M | $39.0M | $41.3M | $50.5M |
| Shareholders' equity | -$17.6M | -$8.9M | $13.4M | $3.2M | $12.6M |
Source: SEC EDGAR filings · CIK 0001822791 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.